Bicara Therapeutics starts FORTIFI-FLEX trial for HPV-negative head and neck cancer

Bicara Therapeutics starts FORTIFI-FLEX trial for HPV-negative head and neck cancer
Bicara launches FORTIFI-FLEX trial

Bicara Therapeutics has launched its FORTIFI-FLEX clinical trial to evaluate a new dosing approach for patients with recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.

The study involves an initial weekly loading dose administered over 12 weeks, followed by an every-three-week maintenance regimen in the first-line setting. The trial aims to assess outcomes in a particularly challenging patient population.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.